John Pullman

DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes

Thomas Blevins, John Pullman, Jaret Malloy et al. · The Journal of Clinical Endocrinology & Metabolism · 2011 · 442 citations · Full text

Efficacy of Inhaled Insulin in Patients With Type 2 Diabetes not Controlled With Diet and Exercise

Ralph A. DeFronzo, Richard M. Bergenstal, William T. Cefalu et al. · Diabetes Care · 2005 · 135 citations · Full text

Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study

Richard Vickers, Glenn Tillotson, Richard Nathan et al. · The Lancet Infectious Diseases · 2017 · 115 citations · Full text

Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study

John Pullman, Jānis Gardovskis, Brett Farley et al. · Journal of Antimicrobial Chemotherapy · 2017 · 100 citations · Full text

MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis

Andrej Spec, John Pullman, George R. Thompson et al. · Journal of Antimicrobial Chemotherapy · 2019 · 83 citations · Full text